Zakari Aliyu, MD
Hematology & Oncology · Baltimore, MDNPI 1679539464
Payments from drug & device makers
Across 70 payments — averaging $36.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Incyte Corporation$168
- E.r. Squibb & Sons, L.L.C.$121
- Merck$100
- AstraZeneca$75
- Pfizer$74
- plus $534 from 18 others
What the payments were for
- Food & beverage$1,13544%
- Education$914%
- Other$1,36353%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 24 | $1,517 |
| Incyte Corporation | 4 | $168 |
| E.r. Squibb & Sons, L.L.C. | 6 | $121 |
| Merck | 5 | $100 |
| AstraZeneca | 4 | $75 |
| Pfizer | 3 | $74 |
| Sobi, Inc | 3 | $70 |
| AVEO Pharmaceuticals, Inc. | 2 | $50 |
| Bayer | 2 | $45 |
| Jazz Pharmaceuticals Inc. | 1 | $39 |
| Genentech USA, Inc. | 2 | $39 |
| Blueprint Medicines Corporation | 1 | $30 |
| Astellas Pharma US Inc | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Karyopharm Therapeutics Inc. | 1 | $25 |
| Coherus Oncology, Inc. | 1 | $24 |
| Beigene USA, Inc. | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Sanofi | 1 | $21 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| GSK | 1 | $19 |
| AbbVie | 1 | $19 |
| Array Biopharma Inc | 1 | $13 |
How this compares
$2,589 in reported general payments places this provider in the 35th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamoxifen Citrate | 27 | $1,186 |
| Anastrozole | 12 | $508 |
| Ondansetron OdtOndansetron | 21 | $250 |
| Prochlorperazine Maleate | 16 | $170 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Baltimore
- Dan ZandbergBaltimore$9.9M
- Ani BalmanoukianBaltimore$6.6M
- Mark MarkowskiBaltimore$5.9M
- Ivana GojoBaltimore$5M
- Suman RaoBaltimore$4.2M
- Patrick FordeBaltimore$4.1M
- Mehmet KocogluBaltimore$3.5M
- Noah HahnBaltimore$3.4M
- Seung Tae LeeBaltimore$2.7M
- Maria BaerBaltimore$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.